Abstract 1500
Background
Docetaxel (Doc) was initially licenced for CRPC (TAX327) but more recently trials showed Doc at HSPC diagnosis improved survival, shifting patterns of use. Higher neutropenic toxicity rates were reported in the HSPC trials, but it is unclear if this was due to the Doc timing or differences in case-mix. We compared sepsis rates for Doc at HSPC and CRPC using routine NHS data for men randomised in STAMPEDE in England.
Methods
STAMPEDE patient data were linked to routine NHS data (Hospital Episode Statistics: HES; Systemic Anti-Cancer Therapy: SACT). Patient note review (ref) linked to NHS data assessed admission rates by HSPC & CRPC Doc at 1 site (N = 44) and were used to develop and validate algorithms for detecting sepsis events across the entire data set. Algorithms were restricted to sepsis-only & sepsis + neutropenia (S+N) (N = 3645). Missing HES CRPC Doc regimens were imputed with HES (N = 3645) or enhanced with SACT (N = 1573). Odds ratios (OR) were calculated for risk of sepsis (OR < 1 = lower risk for HSPC).
Results
Sepsis rates varied by method; for most, rates at CRPC were higher than in TAX327 but similar to or higher than reported STAMPEDE HSPC data.Table:
862P
HSPC Sepsis/Pts | CRPC Sepsis/Pts | % diff | OR, 95% CI | |||
---|---|---|---|---|---|---|
N | % | N | % | |||
Ref | ||||||
2/15 | 13 | 6/22 | 27 | -14 | 0.4 (0.1 - 2.1) | |
HES | ||||||
Sepsis | 69/834 | 8 | 114/1183 | 10 | -2 | 0.9 (0.6 - 1.2) |
S+N | 134/834 | 16 | 148/1183 | 13 | 3 | 1.3 (1.0 - 1.6) |
Imputed | 134/834 | 16 | 489/1351 | 36 | -20 | 0.4 (0.4 - 0.6) |
+ SACT | 41/200 | 21 | 60/297 | 20 | 1 | 1.0 (0.7 - 1.6) |
Conclusions
This analysis does not support the hypothesis that HSPC Doc has a higher sepsis risk than Doc use in CRPC. Sepsis rates found using routine data were higher than in the TAX327 trial but similar to reported “real world” CRPC data. Rates varied by data-identification method used; for most, CRPC sepsis rates were higher or similar to HSPC rates & overall a little higher than the reported STAMPEDE HSPC rate. These data suggest CRPC Doc has a similar or higher sepsis rate than use in HSPC & this should be factored into discussions for men with newly-diagnosed metastatic HSPC and supports Doc use in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The STAMPEDE Trial Group.
Funding
University of Warwick, Warwick Medical School (HM PhD studentship).
Disclosure
M.K.B. Parmar: Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Clovis oncology; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution), The Unit I am Director of also receives educational grants and other non- financial support from a large number of different companies: Other. P. Patel: Advisory / Consultancy: Roche/Genentech. M.R. Sydes: Honoraria (self): Lilly; Honoraria (self), Research grant / Funding (self): Sanofi; Honoraria (self): Janssen; Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): Janssen-Cilag; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Novartis; Research grant / Funding (self): Clovis Oncology. N.D. James: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen; Honoraria (self), Speaker Bureau / Expert testimony: Pierre Fabre; Speaker Bureau / Expert testimony: Ferring; Honoraria (self): Oncogenex; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract